Arena Pharmaceuticals Stock BOERSE MUENCHEN

RN3N

US0400476075

Real-time BOERSE MUENCHEN Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		+6.47%	+10.37%

22-09-19	Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. Executes into Second Amendment to That Certain License Agreement	CI
22-03-15	Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Biotechnology Select Industry Index	CI

Latest news : Arena Pharmaceuticals

22-09-19	Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. Executes into Second Amendment to That Certain License Agreement	CI
22-03-15	Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Biotechnology Select Industry Index	CI
22-03-15	Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P TMI Index	CI
22-03-15	Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Global BMI Index	CI
22-03-11	Pfizer Completes $6.7 Billion Acquisition of Arena Pharmaceuticals	MT
22-03-11	Arena Pharmaceuticals, Inc. Announces Board Changes	CI
22-03-11	Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from NASDAQ Biotechnology Index	CI
22-03-11	Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from NASDAQ Composite Index	CI
22-03-10	Pfizer Inc. completed the acquisition of Arena Pharmaceuticals, Inc..	CI
22-02-23	Arena Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-02-23	Arena Pharmaceuticals Extends Q4 Loss, Reports Higher Revenue	MT
22-02-23	Earnings Flash (ARNA) ARENA PHARMACEUTICALS Reports Q4 Revenue $54,000, vs. Street Est of $0.732M	MT
22-02-23	Earnings Flash (ARNA) ARENA PHARMACEUTICALS Reports Q4 Loss $-2.54, vs. Street Est of $-2.23	MT

More news

Analysts' recommendations: Arena Pharmaceuticals

22-02-09	HC Wainwright Downgrades Arena Pharmaceuticals to Neutral From Buy; Price Target is $100	MT
21-12-21	Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $100 From $93	MT
21-12-14	Citigroup Downgrades Arena Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $100 From $101	MT
21-12-14	Needham Downgrades Arena Pharmaceuticals to Hold From Buy, Drops $80 Price Target	MT
21-12-14	Wells Fargo Downgrades Arena Pharmaceuticals to Equal Weight From Overweight, Lifts Price Target to $100 From $71	MT

More recommendations

Press Releases: Arena Pharmaceuticals

22-03-16	Biopharma Stocks Targeting Crohn's Disease In $13.7 Billion Market (STAB, ARNA, GILD and RDHL)	AQ
22-03-14	Pfizer Completes Acquisition of Arena Pharmaceuticals	AQ
22-03-11	Arena Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
22-03-11	ARENA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
22-03-10	ARENA PHARMACEUTICALS INC : Other Events (form 8-K)	AQ

More press releases

News in other languages: Arena Pharmaceuticals

21-12-17	PUMP / DUMP #42 : Les Tops & Flops de la semaine
21-12-14	USA-Les valeurs à suivre à Wall Street (actualisé)
21-12-14	Planète Bourse : La revue de presse du mardi 14 décembre 2021
21-12-13	Wall Street clôture en baisse, le variant Omicron inquiète de nouveau
21-12-13	Wall Street terughoudend richting vergadering Fed

More news

Managers and Directors: Arena Pharmaceuticals

Manager	Title	Age	Since
Michael Corbo CEO	Chief Executive Officer	-	-
Vanessa Bond DFI	Director of Finance/CFO	-	-
Lamine Mbow CTO	Chief Tech/Sci/R&D Officer	-	2021-09-30

More insiders

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.

Employees

Sector

More about the company